Introduction
Macrophage migration inhibition factor (MIF) is an immunoregulatory cytokine that through interactions with its receptor CD74, recruits and activates macrophages at inflammatory loci. 1, 2 The most important source of MIF is T-helper 2 cells (Th2), where MIF is essential for T-cell activation, but other sources include macrophages, eosinophils, epithelial cells, endothelial cells and keratinocytes. Macrophage MIF is released from macrophages in response to lipopolysaccharide (LPS) and from different cell types in response to proliferative or hypoxic signals. 3, 4 MIF has many functions in the regulation of innate and acquired immunity. For example, MIF initiates inflammation by regulation of pro-inflammatory cytokines including TNFa, IL1 and IL6, 5 and may act in part to antagonize glucocorticoid-mediated suppression of immune cell responses, modifying systemic inflammation. 6 The role of MIF in some human dermatological conditions such as allergic dermatitis, contact dermatitis, AD, psoriasis, vitiligo, alopecia areata, pemphigus vulgaris and bullous pemphigoid has been a focus of research. 1, [7] [8] [9] [10] In humans with AD, MIF concentrations in serum and expression in the epidermis of affected skin correlate with disease severity. 1, 3, 10 Additionally, topical steroid therapy results in a reduction in serum MIF which correlates with clinical resolution. 1 MIF promoter polymorphisms are associated with increased risk for the development of AD, 11 and in other diseases such as rheumatoid arthritis, certain MIF polymorphisms are associated with reduced disease severity. 12 MIF also regulates delayed-type hypersensitivity (IV), and when released from eosinophils can exacerbate human allergic and inflammatory disease such as asthma and AD. 13, 14 It has been reported, 15 that MIF contributes to pollen-induced 16, 17 Clinically, the immunized mice, which produced anti-MIF antibodies, showed reductions in hyperkeratosis, oedema, pruritus and inflammation with histologically significant reductions in dermal eosinophils and mast cells. Collectively, these studies suggest that MIF may control AD, pollen-induced allergic conjunctivitis and pollen dermatitis and could be a target for treatment.
Canine atopic dermatitis (AD) is a common, genetically predisposed, inflammatory and pruritic skin disease thought to affect ≤10% of dogs worldwide. 18, 19 The pathogenesis of canine AD is likely to be, at least in part, associated with dysregulation of cytokine production leading to activation of Th1 cells, Th2 cells, Langerhans cells and monocytes. 20, 21 As there are many similarities between human and canine AD, it is possible that MIF may play a role in the pathogenesis of canine AD. The aim of this study was therefore to evaluate serum MIF concentrations in dogs with AD compared with a control population and assess the correlation with clinical lesion scores.
Methods and materials

Study design
The study had ethical approval from the institute's Veterinary Ethical Review Committee (VERC). Client owned dogs diagnosed with AD were enrolled in the study with informed consent. A diagnosis of AD was made according to accepted criteria, and after ruling out other causes of pruritus. 22 Based on clinical examination and history, dogs were excluded from the study if there was evidence of any other concurrent disease process, including active secondary infection (bacterial or yeast). For the dogs with AD, current medication(s), owner-assessed pruritus Visual Analog Score (pVAS), 23 Canine Atopic Dermatitis Extent and Severity Index, 4 th iteration (CADESI-4 score) 24 and dermatological history were recorded. Dogs were then assigned to three groups according to their current treatment: AD group 1, AD dogs that had not received any systemic or topical steroid therapy for four weeks before sampling; AD group 2, AD dogs currently receiving steroid therapy (systemic and/or topical); and AD group 3, AD dogs currently receiving oclacitinib (Apoquel â , Zoetis; Surrey, UK). Dogs receiving concurrent oclacitinib and topical steroid therapy were included in group 2 (receiving steroid therapy).
Healthy control dogs had no history or clinical signs of skin disease or any other concurrent disease. They were excluded from the study if they were receiving any medication or supplementation apart from routine vaccination, and ecto-and endoparasite control.
Serum was harvested and stored at À80°C for six months until time of analysis.
Migration inhibitory factor ELISA
A canine specific competitive MIF enzyme-linked immunosorbent assay (ELISA) was purchased and used according to manufacturer's instructions (Canine MIF ELISA MBS738733, MyBioSource Inc; San Diego, CA, USA). This ELISA kit contained a 96-well plate pre-coated with an anti-canine MIF monoclonal antibody. Optimization was achieved using various dilutions of canine serum with known standards (as supplied by the manufacturer in the ELISA kit). Undiluted serum (100 lL) was used in the final analysis with samples added to the wells of the 96-well plate in duplicate. The optical density (OD) of each standard, sample and control was determined at 450 nm using the average OD of the duplicate. The OD value was subtracted from the mean blank control to allow construction of a standard curve. The concentration of samples was determined using the corresponding mean absorbance from the standard curve. A positive control sample from a dog with glomerulonephritis was included in the optimization, 25 which gave an average serum MIF concentration of 461 pg/ mL (data not shown). The sensitivity of the assay was 1 pg/mL with a range of detection between 1 pg/mL and 1,000 pg/mL and an intraassay coefficient variation of <10. All samples were batch-thawed and tested on the same day.
Statistical analysis
Statistical analysis was performed with a commercial software package (GraphPad Prism v5; San Diego, CA, USA) and P < 0Á05 was considered significant. Kolmogorov-Smirnov tests showed that the data were not normally distributed. A Wilcoxon-Mann-Whitney U-test was used to determine whether there was a difference between serum MIF concentrations in the control and AD groups MIF concentrations. Multigroup statistical analysis was performed using oneway ANOVA (Kruskal-Wallis test) with Dunn's multiple comparison post-tests. Pearson correlation tests were used to investigate correlation of serum MIF concentrations with CADESI-4 or pVAS.
Results
Treatment groups
Samples were obtained from 17 healthy control dogs and 49 dogs with AD. The AD group consisted of 19 dogs that had not received any topical or systemic steroid therapy (group 1), 21 dogs that were currently receiving steroid therapy which were subcategorized as receiving topical steroid (n = 6; which included two dogs receiving topical steroid only and four dogs receiving topical steroid and oclacitinib), or systemic steroid therapy (n = 12) or combinations of both (n = 3) (group 2), and nine dogs receiving once daily dosing of oclacitinib and no steroid (group 3); four group 3 dogs also received regular injections of allergen-specific immunotherapy (ASIT). Table 1 shows all other concurrent treatments used by some of the dogs in the AD groups 1-3.
Signalment
The control group consisted of 10 breeds and the AD group of 17 breeds, with neutered males slightly overrepresented in both ( Table 2 ). The age range of the control group was 3.1-10.1 years (median 7.5-year-old), and the age range for the AD group was 0.5-11 years (median 4.2-year-old). There was no significant difference between the two groups (P = 0.16). The three most common breeds for the AD dogs were the Labrador retriever (n = 7), golden retriever (n = 6) and cocker spaniel (n = 5).
Serum MIF concentrations
Control dogs had a serum MIF concentration range of 0-214 pg/mL (median 15.63 pg/mL). The dogs with AD had a MIF concentration range of 0-642 pg/mL (median 73.89 pg/mL), which was significantly higher than the control dogs (P < 0.029) (Figure 1 ). There was a significant difference between the three combined treatment groups and control group (P < 0.0001). When further analysis of the AD groups 1-3 was made using Dunn's multiple comparison post-test analysis, there was a significant increase in the serum MIF concentrations in groups 1 (P < 0.001) and 3 (P < 0.01), compared to controls, but not with group 2 compared to the controls (P > 0.05) (Figure 2 and Table 3 ).
There were two dogs in AD group 2 receiving only daily topical steroid therapy; serum MIF concentrations for these dogs were 11.3 and 0 pg/mL. Four of the dogs in AD group 2 were receiving at least twice weekly topical 0.0584% hydrocortisone aceponate, as well as daily oclacitinib at the time of sampling. Serum MIF concentrations for these four dogs were 0 pg/mL. No dogs were receiving systemic steroid therapy and oclacitinib or systemic steroid therapy and ASIT.
The AD group 3 contained four dogs receiving regular (every three to four weeks) injectable ASIT for at least six months (Greer aqueous allergens; Lenoir, GA, USA). These dogs also were receiving daily oclacitinib at the time of sampling and all had serum MIF concentrations greater than the control dogs (Figure 2 , red data points). (1) Bullmastiff (1) Jack Russell terrier (2) Cavalier King Charles spaniel (2) Labrador retriever (2) Cocker spaniel (5) Lurcher (2) Collie and collie crosses (3) (4) The number of dogs of each breed is included in brackets. AD group 1 were not receiving steroids (n = 19), AD group 2 received steroid therapy (n = 21) and AD group 3 were receiving oclacitinib (n = 9). Horizontal black lines represent median values. For the AD group, the red data points identify four dogs on concurrent oclacitinib and injectable immunotherapy. An asterisk above the groups represents statistical significance (**P < 0.01, ***P < 0.001). C control group.
CADESI-4 and pVAS correlation
CADESI-4 data were available for 39 of 49 cases and pVAS data were available for 38 of 49 cases. There was no significant correlation between serum MIF concentrations in the AD group and CADESI-4 ( Figure 3a ) or pVAS scores (Figure 3b ) (r = 0.04, P = 0.78 and r = 0.24, P = 0.78 for CADESI-4 and pVAS, respectively). There also was no significant correlation when comparing the serum MIF concentration of each treatment group to CADESI-4 or pVAS ( Figure 4 ).
Discussion
Dogs diagnosed with AD had increased serum MIF concentrations compared to control dogs in our study. This difference was not observed in dogs that had been treated with steroids, suggesting that glucocorticoids reduce serum MIF concentrations. This needs to be confirmed in a longitudinal study of individual dogs before and after treatment but is consistent with the known ability of glucocorticoids to suppress MIF production in activated T cells. 26 Measurement of serum TNFa also would be useful because it is known that there is interplay between TNFa and MIF, with reductions in MIF correlated with TNFa reductions. 1, 27 The high serum MIF concentrations in dogs receiving oclacitinib are perhaps not surprising. Oclacitinib selectively inhibits Janus-kinase (JAK) enzymes, particularly JAK1-dependent cytokine receptor complexes and is not directly involved in T-cell inhibition. Because Th2 cells are the main source of serum MIF and neither MIF production or secretion involves JAK pathways, 28 oclacitinib would not be expected to reduce serum MIF concentrations. 29 We identified four dogs in AD group 2 receiving topical steroid therapy and concurrent oclacitinib which all had unmeasurable serum MIF concentrations. This probably reflects the actions of topical steroid therapy antagonizing serum MIF rather than the oclacitinib.
In contrast to the reported association in human AD, 1 we found no significant correlation between serum MIF concentrations and the clinical lesion severity or pruritus scores. The MIF serum concentrations obtained from the dogs in this study were only taken at a single timepoint. Therefore, we cannot assess if the dogs receiving oclacitinib or steroid therapy had clinical improvement in their AD phenotype in relation to a reduction in MIF concentrations. For both human and canine AD, visual and subjective improvements in clinical lesions and scores do not always correlate with improvements in inflammatory markers and cytokines within the skin and serum. Nonlesional skin in these patients should not be considered normal, and may be associated with increased numbers of keratinocytes, which are an important source of MIF.
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This may be a reason why correlation between clinical scores and MIF concentrations were not significant. Because MIF is a known pro-inflammatory mediator and is associated with many inflammatory disease processes, the elevated MIF concentrations demonstrated may be purely a marker of inflammation rather than a driver of AD. Further evaluation of the effects of ASIT and serum MIF concentration also will need to be ascertained. In our study, four dogs receiving daily oclacitinib therapy also were receiving regular (every three or four weeks) subcutaneous injections of ASIT and had increased serum MIF concentrations compared with the control group. Although it is not currently known if MIF can modulate the T-regulatory driven immunotherapy response, MIF can promote tumour-associated T-regulatory cells. 31 However, MIF is not thought to have any effect on IL10 or TGFb, both of which are involved in the induction of allergen tolerance. In addition, the effect of injecting foreign antigens in the form of subcutaneous ASIT will induce an innate immune response. 32 Stimulation of the innate immune system by lipopolysaccharide and other ligands such as allergens causes a rapid release of MIF from cells and tissues. 2 This antigenic stimulation also can induce dendritic cells to increase production of IFNa, thus inducing macrophages to release MIF. 5, 33 Combined, these reasons also may explain the elevated MIF concentrations in dogs undergoing this form of therapy. Evaluating larger cohort groups of AD dogs on immunotherapy and serially assessing their serum MIF concentrations prior to, and during immunotherapy will help to assess this further.
The serum MIF concentrations in our canine study were low compared to those reported for healthy humans (canine healthy control 0-214 pg/mL, healthy human 5,000-10,000 pg/mL) 34 with concentrations elevated for neonates. 35 On the one hand, because the assay depends upon a commercial kit and a standard, we cannot eliminate the possibility that the assay detected only a small proportion of the total circulating MIF. On the other, there are already known differences between canine and human cytokine and inflammatory profiles, with most research focusing on differences in the cytokine profiles of inflammatory bowel disease (IBD) between the two species. In human IBD, Th2 cells predominate in chronic disease, yet in dogs with IBD, the profile is of mixed Th1 and Th2 which leads to the expression of different cytokine profiles. 36, 37 In conclusion, to the best of the authors' knowledge, we have identified for the first time that MIF is present in the serum of clinically healthy dogs as in humans, mice, pigs and rats, 32, 38 and this is the first study demonstrating elevated serum MIF in a canine inflammatory disease. We have identified that dogs with AD have significantly higher serum MIF concentrations compared to healthy dogs. Moreover, steroid treatment appears to be associated with decreased MIF concentrations to baseline levels whereas oclacitinib has little effect. Nevertheless, we could not correlate MIF concentrations with lesion or pruritus scores. The role of MIF in the pathogenesis of canine AD therefore warrants further study. This would determine the potential usefulness of MIF-targeted inhibition in canine AD. chiens contrôles. Il n'y avait pas de corr elation entre les concentrations de MIF et les scores cliniques (CADESI-4 ou pVAS). Conclusions et importance clinique -Les concentrations s eriques de MIF sont augment ees chez les chiens AD et le MIF pourraitêtre une cible th erapeutique.
Resumen
Introducci on -la dermatitis at opica (AD) es una enfermedad inflamatoria com un de la piel de los perros. El factor inhibidor de la migraci on de macr ofagos (MIF) inicia la liberaci on de citoquinas proinflamatorias en la AD humana y las concentraciones s ericas se correlacionan con la gravedad de la enfermedad. Hip otesis -las concentraciones de MIF en suero canino aumentan en los perros con AD y se correlacionan con las lesiones cl ınicas y los valores de prurito. Animales -se utilizaron para el estudio perros de propietarios particulares (n = 49) diagnosticados con AD y 17 perros control sanos no afectados. M etodos y materiales -se optimiz o un ELISA MIF comercial para su uso en muestras de suero canino a partir de los casos cl ınicos utilizados. La informaci on sobre el tratamiento, el Indice de Extensi on y Severidad de la Dermatitis At opica Canina, (CADESI-4) y la Escala An aloga Visual de prurito (pVAS) se evaluaron para cada perro en el momento de la recolecci on del suero. Resultados -los perros con AD que no recibieron tratamiento con esteroides y los tratados con oclacitinib tuvieron concentraciones s ericas de MIF significativamente elevadas en comparaci on con los controles. Las concentraciones de MIF no fueron significativamente diferentes en los perros con AD que recibieron esteroides en comparaci on con los controles. No hubo una correlaci on significativa entre las concentraciones de MIF y las puntuaciones cl ınicas (CADESI-4 o pVAS). Conclusiones e importancia cl ınica -las concentraciones s ericas de MIF aumentan en los perros con AD y el MIF podr ıa ser un objetivo para estrategias terape uticas. 
